No Data
No Data
Medicenna Reports Updated Data From ABILITY-1 Trial
Updated MDNA11 Monotherapy and Combination Clinical Data From the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference
Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at SNO Meeting
Medicenna Brief: Reported Q2 Net Loss of $4.2 Million ($0.05 per Share)
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)
No Data